渤健Biogen（BIIB）2024年企业责任报告「NASDAQ」（英文版）（76页）.pdf

1、CORPORATE RESPONSIBILITY REPORTRIGHT:Nandan,a patient advocate who lives with lupus2024OVERVIEWACCESS&HEALTH EQUITYWORKFORCE&CULTURECOMMUNITY IMPACTENVIRONMENTREPORTING 2024 Corporate Responsibility Report1CEO LETTERWe achieved key development milestones across our late-stage pipeline in 2024 and ar

2、e continuing to transform our product portfolio with a focus on diversification and value.”Christopher A.Viehbacher,President and Chief Executive OfficerOver the past year,we continued to make strong progress on our journey to achieve sustainable growth,and we are implementing focused strategies wit

3、h the aim to carry this momentum through 2025 and beyond.Biogens core pharmaceutical business grew for the first time in four years,driven by continued revenue growth from our ongoing product launches supporting our long-term strategy.Building on the groundwork we set last year,this year we remain c

4、ommitted to the key priorities that drove that performance:strong financial discipline following our Fit for Growth Initiative to align Biogens cost base,excellent execution on our new product launches,alignment of resources toward our strongest potential growth drivers,and pursuit of organic growth

5、 from our potentially transformative pipeline of life-changing medications,while supplementing those efforts with strategic transactions.We have evolved our research and development(R&D)model and implemented a new strategic approach to balance our differentiated internal capabilities with external i

6、nvestments in cutting-edge science.We anticipate this will enable greater flexibility,agility and efficiency,all with the goal of translating innovation into advancing new medicines faster.We achieved key development milestones across our late-stage pipeline in 2024 and are continuing to transform o